{Reference Type}: Journal Article
{Title}: Aripiprazole dose associations with metabolic adverse effect: Results from a longitudinal study.
{Author}: Piras M;Popovic I;Ranjbar S;Grosu C;Laaboub N;Sentissi O;Lakhal MH;Gamma F;Plessen KJ;von Gunten A;Conus P;Eap CB;
{Journal}: Schizophr Res
{Volume}: 270
{Issue}: 0
{Year}: 2024 Aug 9
{Factor}: 4.662
{DOI}: 10.1016/j.schres.2024.07.007
{Abstract}: <B>OBJECTIVE: </B>Weight gain, blood lipids and/or glucose dysregulation can follow aripiprazole treatment onset. Whether aripiprazole dosage is associated with an increase in these metabolic parameters remains uncertain. The present study investigates aripiprazole dose associations with weight change, blood glucose, lipids, and blood pressure.<BR><B>METHODS: </B>422 patients taking aripiprazole for a minimum of three weeks to one year were selected from PsyMetab and PsyClin cohorts. Associations between aripiprazole dose and metabolic outcomes were examined using linear mixed-effect models.<BR><B>RESULTS: </B>Aripiprazole dose was associated with weight change when considering its interaction with treatment duration (interaction term: -0.10, p < 0.001). This interaction resulted in greater weight gain for high versus low doses at the beginning of the treatment, this result being overturned at approximately five months, with greater weight increase for low versus high doses thereafter. LDL and HDL cholesterol levels were associated with aripiprazole dose over five months independently of treatment duration, with an average of 0.06 and 0.02 mmol/l increase for each 5 mg increment, respectively (p = 0.033 and p = 0.016, respectively). Furthermore, mean dose increases were associated with greater odds (+30 % per 5 mg increase) of clinically relevant weight gain (i.e., ≥7 %) over one year (p = 0.025).<BR><B>CONCLUSIONS: </B>Aripiprazole dose was associated with one-year weight changes when considering its interaction with treatment duration. Increasing its dose could lead to metabolic worsening over the first five months of treatment, during which minimum effective doses should be particularly preferred.